Dossier assessment
Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
HIV-1 infection in adults who are virologically-suppressed on a stable regimen for ≥ 6 months with no history of virological failure and no known or suspected resistance to any NNRTIs or INIs
Without indication for a treatment switch: indication of lesser benefit; with indication for a treatment switch: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.
Project details
- Project no.
- A18-34
- Commission
- Commission awarded on 24.05.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed